Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers at Stanford have developed a potentially curative treatment strategy for alpha-thalassemia, one of the most common autosomal recessive disorders in the world involving the genes HBA1 and/or HBA2.
Stanford inventors have engineered an adeno-associated virus (AAV) variant on the existing LK03 platform that enables this highly efficient primate-specific serotype for use in rodent preclinical studies.
Mouse embryonic stem (ES) cells are used for generating knockout and knockin mouse models, which are crucial for biomedical research as well as pre-clinical studies.
Stanford researchers developed a technology that efficiently identifies combinations of genetic interventions with lasting, effective therapeutic functions by constructing genetic perturbation libraries containing the desired combination of phenotypes extracted from each cell.
Researchers at Stanford have developed AgeIndex, the first whole-genome epigenetic aging index and method based on Whole Genome Bisulfite Sequencing (WGBS) assays.
Stanford researchers have developed a device that combines one-photon and two-photon microscopy using fast temporal multiplexing enabling 3D alignment between in vivo and ex vivo data for neuroscience and spatial biology applications.
Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.
Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.
Adeno-associated virus (AAV) vectored products are currently leading candidates for gene therapy applications with multiple approved products and many more in clinical trials.